Na Tang
- Oncology top 5%
- CAR-T cell therapy research 6
- Immunology top 10%
- Atherosclerosis and Cardiovascular Diseases 4
- Immune Cell Function and Interaction 3
-
- Cytomegalovirus and herpesvirus research 10
- Herpesvirus Infections and Treatments 3
-
- Virus-based gene therapy research 5
-
- Systemic Lupus Erythematosus Research 4
-
- Renin-Angiotensin System Studies 4
- Partner nations
- ChinaUnited StatesUnited Kingdom
In The Last Decade
Na Tang
51 papers receiving 1.0k citations
Hit Papers
Peers
Comparison fields: 5 of 95
- Oncology 510
- Immunology 271
- Biological Psychiatry 19
- Molecular Biology 456
- Cancer Research 87
Countries citing papers authored by Na Tang
This map shows the geographic impact of Na Tang's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Na Tang with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Na Tang more than expected).
Fields of papers citing papers by Na Tang
This network shows the impact of papers produced by Na Tang. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Na Tang. The network helps show where Na Tang may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Na Tang, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2025 | 1 | |
| 2 | 2025 | 0 | |
| 3 | 2024 | 11 | |
| 4 | 2024 | 7 | |
| 5 | 2023 | 2 | |
| 6 | 2023 | 1 | |
| 7 | 2023 | 5 | |
| 8 | 2022 | 8 | |
| 9 | 2022 | 99 | |
| 10 | 2022 | 65 | |
| 11 | TGF-β inhibition via CRISPR promotes the long-term efficacy of CAR T cells against solid tumorsbreakdown → | 2020 | 293 |
| 12 | 2020 | 14 | |
| 13 | 2020 | 6 | |
| 14 | 2020 | 29 | |
| 15 | 2017 | 9 | |
| 16 | 2017 | 44 | |
| 17 | 2016 | 24 | |
| 18 | 2014 | 42 | |
| 19 | 2012 | 19 | |
| 20 | 2010 | 28 |
About Na Tang
Na Tang is a scholar working on Oncology, Rheumatology and Epidemiology, having authored 52 papers that have together received 1.0k indexed citations. Recurring topics across this work include Cytomegalovirus and herpesvirus research (10 papers), CAR-T cell therapy research (6 papers), Virus-based gene therapy research (5 papers), Systemic Lupus Erythematosus Research (4 papers), Atherosclerosis and Cardiovascular Diseases (4 papers), Renin-Angiotensin System Studies (4 papers), Immune Cell Function and Interaction (3 papers) and Herpesvirus Infections and Treatments (3 papers). The work is most often cited by research in Oncology (510 citations), Immunology (271 citations) and Biological Psychiatry (19 citations). Na Tang has collaborated with scholars based in China, United States and United Kingdom. Frequent co-authors include Haoyi Wang, Xiaofei Wei, Weidong Han, Xingying Zhang, Miaomiao Qiao, Na Li, Chen Cheng, Wei Mu, Chen Cheng and Hua Zhong. Their work appears in journals such as Nature Communications, The Journal of Immunology and PLoS ONE.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.